Esophagogastric Junction Adenocarcinoma
📧 Sign up to get email alerts when something new happens for Esophagogastric Junction Adenocarcinoma.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS research · 2026-04-21Clinical Trial Update: Combination of Immune Checkpoint in Locally Advanced or Metastatic MSI/dMMR Esogastric Adenocarcinomas [Phase 3]
Phase 3 clinical trial investigating a combination of an immune checkpoint inhibitor for locally advanced or metastatic MSI/dMMR esogastric …
-
CLINICAL_TRIALS research · 2026-04-21Clinical Trial Update: Sintilimab Combined With Chemotherapy as Adjuvant Treatment for Phase III GC and GEJ [Phase 2]
Sintilimab plus chemotherapy is being evaluated as adjuvant therapy in a Phase 2 study for gastric adenocarcinoma and esophagogastric juncti…
-
CLINICAL_TRIALS research · 2026-03-25Clinical Trial Update: Retlirafusp Alfa Injection Combined Chemotherapy for Perioperative Treatment of Esophagogastric Junction Adenocarcinoma: A Single-Arm, Phase II Study of Safety and Efficacy [NA]
This is a single-arm Phase II study assessing the safety and efficacy of Retlirafusp Alfa in combination with chemotherapy as perioperative …
-
CLINICAL_TRIALS research · 2026-03-03Clinical Trial Update: Efficacy and Safety of Anti-PD-1, Thymalfasin, and SOX in Neoadjuvant Treatment of cStage III Gastric/Gastroesophageal Junction Adenocarcinoma [Phase 2]
Phase 2 neoadjuvant trial evaluating anti-PD-1 therapy plus thymalfasin and the SOX regimen (S-1 + oxaliplatin) in clinical stage III gastri…
-
CLINICAL_TRIALS research · 2025-12-19Clinical Trial Update: A Phase Ib Trial Evaluating the Safety and Activity of Neoadjuvant Combination of Tislelizumab Plus FLOT for Resectable Esophagogastric Adenocarcinoma [Phase 1]
Phase Ib trial evaluating the safety and activity of neoadjuvant tislelizumab plus the FLOT chemotherapy regimen in patients with resectable…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS research · 2025-12-03Clinical Trial Update: AUGMENTED RESPONSE OF VOLATILE BIOMARKERS IN THE ASSESSMENT OF OESOPHAGOGASTRIC CANCER (AROMA2)
A ClinicalTrials.gov entry for the AROMA2 study examines whether volatile biomarker profiles can augment assessment of esophagogastric cance…
-
CLINICAL_TRIALS research · 2025-08-20Clinical Trial Update: Comparing the Efficacy and Safety of Chemotherapy Combined With or Without Immunotherapy as an Adjuvant Treatment After Radical Surgery for Patients With Resectable Adenocarcinoma of the Esophagogastric Junction of Gastric Cancer [Phase 4]
A Phase 4 clinical trial update evaluating adjuvant chemotherapy with or without immunotherapy after radical surgery for resectable gastric …
-
CLINICAL_TRIALS trial_result · 2025-08-03Clinical Trial Update: A Study of DKN-01 in Combination With Paclitaxel or Pembrolizumab [Phase 1]
Phase 1 study of DKN-01 with paclitaxel or pembrolizumab in esophageal and gastroesophageal cancers has been completed.
-
CLINICAL_TRIALS research · 2025-06-12Clinical Trial Update: Neoadjuvant Immunochemotherapy in Locally Advanced Esophagogastric Junction Adenocarcinoma [Phase 2]
A Phase 2 trial evaluating neoadjuvant immunochemotherapy for locally advanced Esophagogastric Junction adenocarcinoma is currently recruiti…
-
CLINICAL_TRIALS research · 2025-06-10Clinical Trial Update: Planning Treatment for Oesophago-gastric Cancer: a Maintenance Therapy Trial [Phase 2]
A Phase 2 maintenance therapy trial for oesophago-gastric cancer is active but not recruiting, focusing on esophageal, gastroesophageal junc…
-
CLINICAL_TRIALS research · 2025-05-23Clinical Trial Update: Savolitinib for Treating Gastric Cancer and Esophagogastric Junction Adenocarcinoma Patients [Phase 2]
Ongoing phase 2 trial of savolitinib for gastric cancer and esophagogastric junction adenocarcinoma; the study is currently not recruiting.
-
CLINICAL_TRIALS trial_result · 2025-02-20Clinical Trial Update: Chemotherapy and Pembrolizumab, Followed by Pembrolizumab and Olaparib As Firstline Therapy in Her-2 Negative Gastric/GEJ Adenocarcinoma [Phase 2]
This Phase 2 trial update indicates completion of a first-line therapy approach for HER2-negative gastric/GEJ adenocarcinoma using chemother…
-
CLINICAL_TRIALS withdrawal · 2025-02-06Clinical Trial Update: Molecular Analysis of Gastric and OEsophageal Cancers STudy
A molecular analysis study of gastric and esophageal cancers has been withdrawn from clinical trials.
-
CLINICAL_TRIALS trial_result · 2025-01-15Clinical Trial Update: PD1 Combined With Chemotherapy for Adjuvant Treatment of Gastric Cancer [Phase 3]
Phase 3 trial update on PD-1 inhibitor in combination with chemotherapy as adjuvant treatment for gastric cancer, with the study currently a…
-
CLINICAL_TRIALS research · 2024-10-16Clinical Trial Update: Right Versus Left Thoracic Surgical Approaches for Siewert II Gastroesophageal Junction Adenocarcinoma [NA]
An ongoing clinical trial is evaluating right versus left thoracic surgical approaches for Siewert Type II gastroesophageal junction adenoca…
-
CLINICAL_TRIALS research · 2024-08-28Clinical Trial Update: Nimotuzumab Combined With Paclitaxel for Recurrent Metastatic Gastric or Esophagogastric Junction Adenocarcinoma [Phase 3]
A Phase 3 trial evaluating nimotuzumab in combination with paclitaxel for recurrent/metastatic gastric cancer or esophagogastric junction ad…
-
CLINICAL_TRIALS research · 2024-07-01Clinical Trial Update: Perioperative Treatment of Resectable Adenocarcinoma of Esophagogastric Junction by Immunotherapy (Adebrelimab) Combined With Chemotherapy (XELOX): a Prospective, Single-center, Feasibility Study [Phase 2]
Phase 2 feasibility study evaluating perioperative immunotherapy with adebrelimab combined with XELOX (capecitabine and oxaliplatin) for res…
-
CLINICAL_TRIALS trial_result · 2024-01-05Clinical Trial Update: Postoperative Immunotherapy vs Standard Chemotherapy for Gastric Cancer With High Risk for Recurrence [Phase 2]
Phase 2 clinical trial comparing postoperative immunotherapy to standard chemotherapy for high-risk gastric cancer after surgery.
-
CLINICAL_TRIALS trial_result · 2021-08-24Clinical Trial Update: PD-1 Monoclonal Antibody Combined With FLOT Regimen for Neoadjuvant Therapy of Gastric Adenocarcinoma [Phase 2]
Phase 2 trial investigating PD-1 monoclonal antibody with FLOT chemotherapy as neoadjuvant therapy for gastric adenocarcinoma and tumors at …
-
CLINICAL_TRIALS trial_result · 2021-07-01Clinical Trial Update: Camrelizumab Combined With Apatinib for Advanced Gastric or Esophagogastric Adenocarcinoma [Phase 2]
Phase 2 trial update evaluating camrelizumab in combination with apatinib for advanced gastric/GEJ adenocarcinoma.
-
CLINICAL_TRIALS trial_result · 2021-04-13Clinical Trial Update: FOLFOX6 Versus mFOLFIRINOX as First Line Chemotherapy in Metastatic Gastric Cancer or Esophagogastric Junction Adenocarcinoma (Type II-III) [Phase 2]
A Phase 2 clinical trial comparing FOLFOX6 vs mFOLFIRINOX as first-line chemotherapy in metastatic gastric cancer or esophagogastric junctio…
-
CLINICAL_TRIALS trial_result · 2020-02-28Clinical Trial Update: Palliative Short-course Hypofractionated Radiotherapy Followed by Chemotherapy in Adenocarcinoma of the Esophagus or Esophagogastric Junction Trial - a Phase II Clinical Trial Protocol. [Phase 2]
Phase II clinical trial protocol assessing palliative short-course hypofractionated radiotherapy followed by chemotherapy for adenocarcinoma…
-
CLINICAL_TRIALS trial_result · 2019-12-23Clinical Trial Update: Perioperative Combination Chemotherapy Versus Chemoradiation for Locally Advanced EGJ Adenocarcinoma [Phase 3]
A Phase 3 trial comparing perioperative combination chemotherapy to chemoradiation for locally advanced Esophagogastric Junction adenocarcin…
-
CLINICAL_TRIALS trial_result · 2015-05-19Clinical Trial Update: Paclitaxel Plus Capecitabine With Capecitabine Maintenance Treatment in Metastatic Adenocarcinoma of the Stomach or Esophagogastric Junction [Phase 3]
A Phase 3 trial evaluating paclitaxel plus capecitabine with capecitabine maintenance in metastatic adenocarcinoma of the stomach or esophag…
-
CLINICAL_TRIALS trial_result · 2013-12-05Clinical Trial Update: AMG 102 Plus ECX for Unresectable Locally Advanced or Metastatic Gastric or Esophagogastric Junction Cancer [Phase 1, Phase 2]
A combination of AMG 102 with ECX (epirubicin, cisplatin, capecitabine) was evaluated in Phase 1/2 for unresectable locally advanced or meta…